Hugel

Venture Capital
PORTFOLIO

Industry : Bio Medical Product

Investment Year : 2013
Investment Type : Growth Stage

SBC invested Hugel in Growth Stage in 2013. Since then Hugel’s market share in domestic and Southeast Asian market has been increased and Hugel achieved sharp increase in revenue and operating profit.

Hugel was established in 2001 by cosmetic surgery experts to commercialize material for cosmetic surgery. Company’s core product is Rinyum, commonly known as Botox. It’s a poisonous material included in BTWC. There is high entry barrier to manufacture Rinyum, because Biosafety Level 3 are required. 

Globally, seven pharmaceutical companies are forming an oligopoly in Rinyum market. Hugel has secured the original technology and equipment through years of R&D investment. The company also secured price competitiveness through achieving process improvement such as maximizing lyophilization rate and using lesser protein concentration than its competitors to get same effects. 

SBC invested Hugel in Growth Stage in 2013. Since then Hugel’s market share in domestic and Southeast Asian market has been increased and Hugel achieved sharp increase in revenue and operating profit.
Hugel is planning to go public in 2015. SBC is going to secure multiple x3~x4 level of profit through division sale.